Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | CASP3 | P42574 | 1/20 | 0.38 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.38 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.38 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.38 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 7/20 | 0.34 |
| ▸ | ACACB | O00763 | 2/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13025726 | 0.88 | FFAR4 (0.41) | RAB9ANPC1CASP3SENP8NLRP3 | |
| SCHEMBL13025811 | 0.88 | NPC1 (0.37) | RAB9ANPC1CASP3SENP8NLRP3 | |
| SCHEMBL13025951 | 0.87 | FFAR4 (0.40) | FFAR4 | |
| SCHEMBL13025958 | 0.85 | FFAR4 (0.39) | FFAR4 | |
| SCHEMBL13025988 | 0.85 | NPC1 (0.35) | RAB9ANPC1CASP3SENP8NLRP3 | |
| SCHEMBL13025777 | 0.85 | FFAR1 (0.39) | RAB9ANPC1FFAR4ACACBFFAR1 | |
| SCHEMBL13066972 | 0.83 | MAOB (0.33) | FFAR4 | |
| SCHEMBL12834325 | 0.83 | NPC1 (0.38) | RAB9ANPC1CASP3SENP8NLRP3 | |
| SCHEMBL12834178 | 0.83 | ACACB (0.34) | FFAR4ACACBFFAR1MEN1KMT2A | |
| SCHEMBL13026013 | 0.82 | MAOB (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7838087-B2 | Benzene derivative, liquid crystal composition and liquid crystal display device | CHISSO CORPORATION (JP) | 2010-11-23 | — | — | US | disclosed |
| US-20070200092-A1 | Benzene Derivative, Liquid Crystal Composition And Liquid Crystal Display Device | JNC PETROCHEMICAL CORPORATION (JP) | 2007-08-30 | — | — | US | disclosed |
| US-20070200092-A1 | Benzene Derivative, Liquid Crystal Composition And Liquid Crystal Display Device | JNC PETROCHEMICAL CORPORATION (JP) | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070200092-A1 | Benzene Derivative, Liquid Crystal Composition And Liquid Crystal Display Device | CCND2, YBX1, CNKSR1 | RAB9A 2262/4885NPC1 3260/4885CASP3 2175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.